Targeted therapy for triple-negative breast cancer using antibody-drug conjugates
Synergistic Targeted Therapy of Antibody-Drug Conjugates for Triple-Negative Breast Cancer
This study is working on new treatments for triple-negative breast cancer that aim to target cancer cells directly while being kinder to healthy cells, so patients can have better outcomes with fewer side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11001831 on NIH RePORTER |
What this research studies
This research focuses on developing targeted therapies specifically for triple-negative breast cancer (TNBC), a type of breast cancer known for its aggressive nature and poor prognosis. The approach involves creating antibody-drug conjugates (ADCs) that can selectively target cancer cells while minimizing damage to normal cells. By identifying specific surface receptors on TNBC cells, the researchers aim to design therapies that effectively eliminate cancer cells with fewer side effects. The study includes both laboratory and animal model evaluations to assess the safety and effectiveness of these novel treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded well to standard treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less harmful treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promise in using targeted therapies for other types of cancers, indicating potential success for this novel approach in TNBC.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Liu, Runhua Runa — University of Alabama at Birmingham
- Study coordinator: Liu, Runhua Runa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.